Export file:

Format

  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text

Content

  • Citation Only
  • Citation and Abstract

In vitro activity of some flavonoid derivatives on human leukemic myeloid cells: evidence for aminopeptidase-N (CD13) inhibition, antiproliferative and cell death properties

1 Centre de Recherche des Cordeliers, INSERM UMRS1138, Sorbonne Universités UPMC Paris 06, Université Paris Descartes Sorbonne Paris Cité, F-75006 Paris, France
2 Assistance Publique des Hôpitaux de Paris, France
3 Centre de Recherche des Cordeliers, INSERM UMRS872 (2011-2012), Sorbonne Universités UPMC Paris 06, Université Paris Descartes Sorbonne Paris Cité, F-75006 Paris, France
4 Institut Curie, Departement Recherche, CNRS UMR3666, INSERM U1143, F-75005 Paris, France

† Senior co-authorship.

Topical Section: Cells Signalling and Signal Transduction

Leukemia cells from patients with acute myeloid leukemia (AML) display high proliferative capacity and are resistant to death. Membrane-anchored aminopeptidase-N/CD13 is a potential drug target in AML. Clinical research efforts are currently focusing on targeted therapies that induce death in AML cells. We previously developed a non-cytotoxic APN/CD13 inhibitor based on flavone-8-acetic acid scaffold, the 2',3-dinitroflavone-8-acetic acid (1). In this context, among the variously substituted 113 compounds further synthesized and tested for evaluation of their effects on APN/CD13 activity, proliferation and survival in human AML U937 cells, eight flavonoid derivatives emerged: 2',3-dinitro-6-methoxy-flavone-8-acetic acid (2), four compounds (36) with the 3-chloro-2,3-dihydro-3-nitro-2-phenyl-4H-1-benzopyran-4-one structure, and three (79) with the 3-chloro-3,4-dihydro-4-hydroxy-3-nitro-2-phenyl-2H-1-benzopyran framework. Different structure-activity relationships were observed between APN/CD13 activity and growth/survival processes. We showed that compound 2, but not benzopyran derivatives 39, inhibited APN activity (although to a less degree than 1). Both 1 and 2 did not affect AML cell proliferation and survival, indicating that CD13’s APN activity is not required for these processes. In contrast, benzopyran compounds 39 inhibited in a concentration-dependent manner the growth of U937 cells by inducing death as evidenced by phosphatidylserine externalization. Cell death was associated with the presence of geminal nitro group and chlorine at the 3-position of the 2H-1-benzopyran scaffold. The presence of other substituents such as CH2COOH or CH2CH=CH2 groups at the 8-position, NO2 or I substituents at the 2'- or 3'-position, OCH3 or OCH2C6H5 groups at the 4'-position did not affect cell death. Importantly, the inhibitory effects evidenced with compounds 79 were not due to their potential decomposition into the corresponding (Z)-(2chloro-2-nitroethenyl)benzene and salicylaldehyde. Based on these preliminary data, the 3-chloro,3-nitro-2H-1-benzopyran derivatives could be classified as a new group of compounds with promising antitumor properties; this study therefore provides the opportunity to explore their potential efficiency in AML patients’ cells ex vivo.
  Figure/Table
  Supplementary
  Article Metrics

References

1. King ME, Rowe JM (2007) Recent developments in acute myelogenous leukemia therapy. Oncologist 12 Suppl 2: 14-21.

2. Robak T, Wierzbowska A (2009) Current and emerging therapies for acute myeloid leukemia. Clin Ther 31 Pt 2: 2349-2370.

3. Steele VE, Boone CW, Dauzonne D, et al. (2002) Correlation between electron-donating ability of a series of 3-nitroflavones and their efficacy to inhibit the onset and progression of aberrant crypt foci in the rat colon. Cancer Res 62: 6506-6509.

4. Cardenas M, Marder M, Blank VC, et al. (2006) Antitumor activity of some natural flavonoids and synthetic derivatives on various human and murine cancer cell lines. Bioorg Med Chem 14: 2966-2971.    

5. Li Y, Fang H, Xu W (2007) Recent advance in the research of flavonoids as anticancer agents. Mini Rev Med Chem 7: 663-678.    

6. Singh M, Kaur M, Silakari O (2014) Flavones: an important scaffold for medicinal chemistry. Eur J Med Chem 84: 206-239.    

7. Chabot GG, Touil YS, Pham MH, et al. (2010) Flavonoids in cancer prevention and therapy: chemistry, pharamcology, mechanisms of action, and perspectives for cancer drugdiscovery. In: Moulay A, editor. Alternative and complementary therapies for cancer. Springer US, 583-612.

8. Hou DX, Kumamoto T (2010) Flavonoids as protein kinase inhibitors for cancer chemoprevention: direct binding and molecular modeling. Antioxid Redox Signal 13: 691-719.    

9. Ravishankar D, Rajora AK, Greco F, et al. (2013) Flavonoids as prospective compounds for anti-cancer therapy. Int J Biochem Cell Biol 45: 2821-2831.    

10. Li-Weber M (2009) New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treat Rev 35: 57-68.    

11. Liesveld JL, Abboud CN, Lu C, et al. (2003) Flavonoid effects on normal and leukemic cells. Leuk Res 27: 517-527.    

12. Newcomb EW (2004) Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity. Anticancer Drugs 15: 411-419.    

13. Cheng S, Gao N, Zhang Z, et al. (2010) Quercetin induces tumor-selective apoptosis through downregulation of Mcl-1 and activation of Bax. Clin Cancer Res 16: 5679-5691.    

14. Fathi AT, Karp JE (2009) New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines. Curr Oncol Rep 11: 346-352.    

15. Blum W, Phelps MA, Klisovic RB, et al. (2010) Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias. Haematologica 95: 1098-1105.    

16. Karp JE, Smith BD, Resar LS, et al. (2011) Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood 117: 3302-3310.    

17. Zeidner JF, Foster MC, Blackford AL, et al. (2015) Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica 100: 1172-1179.    

18. Bauvois B, Puiffe ML, Bongui JB, et al. (2003) Synthesis and biological evaluation of novel flavone-8-acetic acid derivatives as reversible inhibitors of aminopeptidase N/CD13. J Med Chem 46: 3900-3913.    

19. Quiney C, Dauzonne D, Kern C, et al. (2004) Flavones and polyphenols inhibit the NO pathway during apoptosis of leukemia B-cells. Leuk Res 28: 851-861.    

20. Piedfer M, Bouchet S, Tang R, et al. (2013) p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells. Biochim Biophys Acta 1833: 1316-1328.    

21. Bauvois B, Dauzonne D (2006) Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects. Med Res Rev 26: 88-130.

22. Bouchet S, Tang R, Fava F, et al. (2016) The CNGRC-GG-D(KLAKLAK)2 peptide induces a caspase-independent, Ca2+-dependent death in human leukemic myeloid cells by targeting surface aminopeptidase N/CD13. Oncotarget 7: 19445-19467.

23. Klobusicka M, Kusenda J, Babusikova O (2005) Myeloid enzymes profile related to the immunophenotypic characteristics of blast cells from patients with acute myeloid leukemia (AML) at diagnosis. Neoplasma 52: 211-218.

24. Taussig DC, Pearce DJ, Simpson C, et al. (2005) Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 106: 4086-4092.    

25. Piedfer M, Dauzonne D, Tang R, et al. (2011) Aminopeptidase-N/CD13 is a potential proapoptotic target in human myeloid tumor cells. Faseb J 25: 2831-2842.    

26. Wickstrom M, Larsson R, Nygren P, et al. (2011) Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Sci 102: 501-508.    

27. Dauzonne D, Folléas B, Martinez L, et al. (1997) Synthesis and in vitro cytotoxicity of a series of 3-aminoflavones. . Eur J Med Chem 32: 71-82.    

28. Dauzonne D, Demerseman P (1990) A convenient synthesis of 3-chloro-3,4-dihydro-4-hydroxy-3-nitro-2-p henyl-2H-1-benzopyrans. Synthesis 1: 66-70.

29. Dauzonne D, Grandjean C (1992) Synthesis of 2-Aryl-3-nitro-4H-1-benzopyran-4-ones. Synthesis 7: 677-680.

30. Pham MH, Auzeil N, Regazzetti A, et al. (2007) Identification of new flavone-8-acetic acid metabolites using mouse microsomes and comparison with human microsomes. Drug Metab Dispos 35: 2023-2034.    

31. Ceccaldi A, Rajavelu A, Champion C, et al. (2011) C5-DNA methyltransferase inhibitors: from screening to effects on zebrafish embryo development. Chembiochem 12: 1337-1345.    

32. Lanotte M, Martin-Thouvenin V, Najman S, et al. (1991) NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77: 1080-1086.

33. Laouar A, Wietzerbin J, Bauvois B (1993) Divergent regulation of cell surface protease expression in HL-60 cells differentiated into macrophages with granulocyte macrophage colony stimulating factor or neutrophils with retinoic acid. Int Immunol 5: 965-973.    

34. Laouar A, Villiers C, Sanceau J, et al. (1993) Inactivation of interleukin-6 in vitro by monoblastic U937 cell plasma membranes involves both protease and peptidyl-transferase activities. Eur J Biochem 215: 825-831.    

35. Broker LE, Kruyt FA, Giaccone G (2005) Cell death independent of caspases: a review. Clin Cancer Res 11: 3155-3162.    

36. Wang ZB, Liu YQ, Cui YF (2005) Pathways to caspase activation. Cell Biol Int 29: 489-496.    

37. Antczak C, De Meester I, Bauvois B (2001) Transmembrane proteases as disease markers and targets for therapy. J Biol Regul Homeost Agents 15: 130-139.

38. Bauvois B (2001) Transmembrane proteases in focus: diversity and redundancy? J Leukoc Biol 70: 11-17.

39. Bauvois B (2004) Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? Oncogene 23: 317-329.    

40. Mina-Osorio P (2008) The moonlighting enzyme CD13: old and new functions to target. Trends Mol Med 14: 361-371.    

41. Antczak C, De Meester I, Bauvois B (2001) Ectopeptidases in pathophysiology. Bioessays 23: 251-260.

42. Grujic M, Renko M (2002) Aminopeptidase inhibitors bestatin and actinonin inhibit cell proliferation of myeloma cells predominantly by intracellular interactions. Cancer Lett 182: 113-119.    

43. Winnicka B, O'Conor C, Schacke W, et al. (2010) CD13 is dispensable for normal hematopoiesis and myeloid cell functions in the mouse. J Leukoc Biol 88: 347-359.    

44. Scaffidi C, Schmitz I, Zha J, et al. (1999) Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J Biol Chem 274: 22532-22538.    

45. Galluzzi L, Vitale I, Abrams JM, et al. (2012) Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 19: 107-120.    

46. Galluzzi L, Kepp O, Krautwald S, et al. (2014) Molecular mechanisms of regulated necrosis. Semin Cell Dev Biol 35: 24-32.    

47. Pasparakis M, Vandenabeele P (2015) Necroptosis and its role in inflammation. Nature 517: 311-320.    

48. Baritaud M, Boujrad H, Lorenzo HK, et al. (2010) Histone H2AX: The missing link in AIF-mediated caspase-independent programmed necrosis. Cell Cycle 9: 3166-3173.    

49. Vanden Berghe T, Linkermann A, Jouan-Lanhouet S, et al. (2014) Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol 15: 135-147.

50. Bonora M, Wieckowski MR, Chinopoulos C, et al. (2015) Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition. Oncogene 34: 1475-1486.    

51. Yuan Z, Long C, Junming T, et al. (2012) Quercetin-induced apoptosis of HL-60 cells by reducing PI3K/Akt. Mol Biol Rep 39: 7785-7793.    

52. Lee WJ, Hsiao M, Chang JL, et al. (2015) Quercetin induces mitochondrial-derived apoptosis via reactive oxygen species-mediated ERK activation in HL-60 leukemia cells and xenograft. Arch Toxicol 89: 1103-1117.    

53. Chen YC, Shen SC, Lee WR, et al. (2002) Wogonin and fisetin induction of apoptosis through activation of caspase 3 cascade and alternative expression of p21 protein in hepatocellular carcinoma cells SK-HEP-1. Arch Toxicol 76: 351-359.    

54. Hu C, Xu M, Qin R, et al. (2015) Wogonin induces apoptosis and endoplasmic reticulum stress in HL-60 leukemia cells through inhibition of the PI3K-AKT signaling pathway. Oncol Rep 33: 3146-3154.

55. Hsiao PC, Lee WJ, Yang SF, et al. (2014) Nobiletin suppresses the proliferation and induces apoptosis involving MAPKs and caspase-8/-9/-3 signals in human acute myeloid leukemia cells. Tumour Biol 35: 11903-11911.    

56. Budhraja A, Gao N, Zhang Z, et al. (2012) Apigenin induces apoptosis in human leukemia cells and exhibits anti-leukemic activity in vivo. Mol Cancer Ther 11: 132-142.    

57. Ruela-de-Sousa RR, Fuhler GM, Blom N, et al. (2010) Cytotoxicity of apigenin on leukemia cell lines: implications for prevention and therapy. Cell Death Dis 1: e19.    

58. Park C, Lee WS, Go SI, et al. (2014) Morin, a flavonoid from moraceae, induces apoptosis by induction of BAD protein in human leukemic cells. Int J Mol Sci 16: 645-659.    

59. Gao H, Liu Y, Li K, et al. (2016) Hispidulin induces mitochondrial apoptosis in acute myeloid leukemia cells by targeting extracellular matrix metalloproteinase inducer. Am J Transl Res 8: 1115-1132.

60. Cardenas MG, Blank VC, Marder MN, et al. (2012) 2'-Nitroflavone induces apoptosis and modulates mitogen-activated protein kinase pathways in human leukaemia cells. Anticancer Drugs 23: 815-826.    

61. Chang H, Lin H, Yi L, et al. (2010) 3,6-Dihydroxyflavone induces apoptosis in leukemia HL-60 cell via reactive oxygen species-mediated p38 MAPK/JNK pathway. Eur J Pharmacol 648: 31-38.    

62. Rosato RR, Dai Y, Almenara JA, et al. (2004) Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation. Leukemia 18: 1780-1788.    

63. Delmulle L, Vanden Berghe T, Keukeleire DD, et al. (2008) Treatment of PC-3 and DU145 prostate cancer cells by prenylflavonoids from hop (Humulus lupulus L.) induces a caspase-independent form of cell death. Phytother Res 22: 197-203.

64. Wu PP, Kuo SC, Huang WW, et al. (2009) (-)-Epigallocatechin gallate induced apoptosis in human adrenal cancer NCI-H295 cells through caspase-dependent and caspase-independent pathway. Anticancer Res 29: 1435-1442.

65. Zhang Y, Yang ND, Zhou F, et al. (2012) (-)-Epigallocatechin-3-gallate induces non-apoptotic cell death in human cancer cells via ROS-mediated lysosomal membrane permeabilization. PLoS One 7: e46749.    

66. Wang G, Wang JJ, Yang GY, et al. (2012) Effects of quercetin nanoliposomes on C6 glioma cells through induction of type III programmed cell death. Int J Nanomedicine 7: 271-280.    

67. Liao H, Bao X, Zhu J, et al. (2015) O-Alkylated derivatives of quercetin induce apoptosis of MCF-7 cells via a caspase-independent mitochondrial pathway. Chem Biol Interact 242: 91-98.    

68. Lindsay CK, Gomez DE, Thorgeirsson UP (1996) Effect of flavone acetic acid on endothelial cell proliferation: evidence for antiangiogenic properties. Anticancer Res 16: 425-431.

69. Granci V, Dupertuis YM, Pichard C (2010) Angiogenesis as a potential target of pharmaconutrients in cancer therapy. Curr Opin Clin Nutr Metab Care 13: 417-422.    

70. Prasad S, Phromnoi K, Yadav VR, et al. (2010) Targeting inflammatory pathways by flavonoids for prevention and treatment of cancer. Planta Med 76: 1044-1063.    

71. Asensi M, Ortega A, Mena S, et al. (2011) Natural polyphenols in cancer therapy. Crit Rev Clin Lab Sci 48: 197-216.    

72. Pham MH, Dauzonne D, Chabot GG (2016) Not flavone-8-acetic acid (FAA) but its murine metabolite 6-OH-FAA exhibits remarkable antivascular activities in vitro. Anti-Cancer Drugs 27: 398-406.    

73. Granja A, Pinheiro M, Reis S (2016) Epigallocatechin Gallate Nanodelivery Systems for Cancer Therapy. Nutrients 8: 307.    

74. Bauvois B (2012) New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 1825: 29-36.

75. Trujillo A, McGee C, Cogle CR (2012) Angiogenesis in acute myeloid leukemia and opportunities for novel therapies. J Oncol 2012: 128608.

76. Haouas H (2014) Angiogenesis and acute myeloid leukemia. Hematology 19: 311-323.    

77. Klein G, Vellenga E, Fraaije MW, et al. (2004) The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol 50: 87-100.    

78. Bouchet S, Tang R, Fava F, et al. (2014) Targeting CD13 (aminopeptidase-N) in turn downregulates ADAM17 by internalization in acute myeloid leukaemia cells. Oncotarget 5: 8211-8222.    

79. Bouchet S, Bauvois B (2014) Neutrophil Gelatinase-Associated Lipocalin (NGAL), Pro-Matrix Metalloproteinase-9 (pro-MMP-9) and Their Complex Pro-MMP-9/NGAL in Leukaemias. Cancers (Basel) 6: 796-812.    

Copyright Info: © 2016, Brigitte Bauvois, et al., licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Article outline

Show full outline
Copyright © AIMS Press All Rights Reserved